PDGFRB and hepatocellular carcinoma: Sorafenib, a multikinase inhibitor whose targets include, amongst others, the RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature, remained the standard of care of advanced HCC for more than a decade following its initial approval in 2007 (Llovet et al. 2008).